Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:110-4. doi: 10.1007/s00406-008-5022-2.

Neuroenhancement: status quo and perspectives.

Author information

1
Department of Psychiatry, University Medical Center, Hauptstrasse 5, Freiburg, Germany. Claus.normann@uniklinik-freiburg.de

Abstract

Neuroenhancement is a pharmacological attempt to increase cognitive performance in healthy humans. Strategies to improve learning and memory aim at plasticity pathways in the brain; phosphodiesterase inhibitors such as rolipram and NMDA-modulating drugs like donepezil and D: -cycloserine have been tested in clinical trials. Modafinil and methylphenidate are used to increase attention and vigilance. Other fields of intense research include mood, social interaction and sexual performance. So far, all clinical trials of neuroenhancing drugs have either failed or demonstrated only very limited efficacy. However, the high demand for neuroenhancement and the intense research efforts might come up with more efficacious drugs in the near future implying the need for an extended ethical discussion in society.

PMID:
18985306
DOI:
10.1007/s00406-008-5022-2
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center